Objective: We aimed to investigate the association of combined finerenone and tripterygium glycosides (TG) therapy with proteinuria reduction in patients with diabetic kidney disease (DKD). Methods: This retrospective cohort study included patients with DKD and an estimated glomerular filtration rate (eGFR) of 15 to 0.05). However, the incidences of hyperkalemia and liver and kidney-related adverse events were also comparable between the groups (all P > 0.05). Conclusion: In patients with DKD and an eGFR of 15 to <60 mL/min/1.73 m 2 , combination therapy with TG and finerenone was associated with a greater reduction in UACR than finerenone alone, without a significant increase in the risk of the assessed adverse events. Further evaluation in prospective randomized trials is warranted.